Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020
Authors:
- Sergio García-FernándezSGSergio García-Fernández
- Jorge CalvoJCJorge Calvo
- Emilia CercenadoECEmilia Cercenado
- Ana Isabel Suárez-BarrenecheaASAna Isabel Suárez-Barrenechea
- María Fernández-BillónMFMaría Fernández-Billón
- Francisco Javier CastilloFCFrancisco Javier Castillo
- Lydia Gálvez-BenítezLGLydia Gálvez-Benítez
- Fe TubauFTFe Tubau
- Ruth Esther Figueroa CerónRCRuth Esther Figueroa Cerón
- Alicia Hernández-CabezasAHAlicia Hernández-Cabezas
- Fernando González RomoFRFernando González Romo
- María Carmen FariñasMFMaría Carmen Fariñas
Open Access
- 22 March 2023
- journal article
- research article
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 36 (3) , 302-309
Abstract
Objectives. To determine susceptibility to the novel β-lactam/β-lactamase inhibitor combination imipenem/relebactam in clinical isolates recovered from intra-abdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream (BSI) infections in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study in SPAIN during 2016 – 2020. Methods. Broth microdilution MICs for imipenem/relebactam and comparators were determined by a central laboratory against isolates of Enterobacterales and Pseudomonas aeruginosa. MICs were interpreted using EUCAST-2021 breakpoints. Results. In total, 5,210 Enterobacterales and 1,418 P. aeruginosa clinical isolates were analyzed. Imipenem/relebactam inhibited 98.8% of Enterobacterales. Distinguishing by source of infection susceptibility was 99.1% in BSI, 99.2% in IAI, 97.9% in RTI, and 99.2% in UTI. Of intensive care unit isolates (ICU) 97.4% were susceptible and of non-ICU isolates 99.2% were susceptible. In Enterobacterales, activity against Class A, Class B and Class D carbapenemases was 96.2%, 15.4% and 73.2%, respectively. In P. aeruginosa, imipenem/relebactam was active in 92.2% of isolates. By source of infection it was 94.8% in BSI, 92.9% in IAI, 91.7% in RTI, and 93.1% in UTI. An 88.7% of ICU isolates and 93.6% of non-ICU isolates were susceptible to imipenem/relebactam. Imipenem/relebactam remained active against P. aeruginosa ceftazidime-resistant (76.3%), cefepime-resistant (73.6%), imipenem-resistant (71.5%) and piperacillin-resistant (78.7%) isolates. Of all multidrug-resistant or difficult-to-treat resistance P. aeruginosa isolates, 75.1% and 46.2%, respectively, were susceptible to imipenem/relebactam. Conclusions. Imipenem/relebactam showed high rates of susceptibility in Enterobacterales and P. aeruginosa isolates from different sources of infection as well as depending on patients’ location (ICU or non-ICU scenarios).Keywords
This publication has 8 references indexed in Scilit:
- Carbapenem-Resistant Enterobacterales, Carbapenem Resistant Organisms, Carbapenemase-Producing Enterobacterales, and Carbapenemase-Producing Organisms: Terminology Past its “Sell-By Date” in an Era of New Antibiotics and Regional Carbapenemase EpidemiologyClinical Infectious Diseases, 2020
- In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples – SMART Surveillance Europe 2015–2017Journal of Medical Microbiology, 2020
- In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients – SMART Surveillance United States 2015–2017International Journal of Antimicrobial Agents, 2020
- Antimicrobial Resistance: Implications and CostsInfection and Drug Resistance, 2019
- Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line AgentsClinical Infectious Diseases, 2018
- In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)Antimicrobial Agents and Chemotherapy, 2016
- Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosaJournal of Antimicrobial Chemotherapy, 2013
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistanceClinical Microbiology and Infection, 2012